Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis Biotherapeutics develops and sells ZORYVE topical treatments for psoriasis, atopic dermatitis, and seborrheic dermatitis. It last closed at $27.33 on Nov 17, up 0.66% on the day. The average 12-month price target from 3 analysts is $44.00 (+61.0% from the last close), with a high of $48.00 and a low of $40.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ARQT, 0% of them bullish and 100% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From ARQT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on ARQT in the past 90 days. The average target is $44.00, with a high of $48.00 and a low of $40.00, compared with the last close of $27.33.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 5 | TD Cowen | Maintained | Buy | $40 |
| Oct 19 | Guggenheim | Target raised | Buy | $38 → $44 |
| Oct 15 | Cantor Fitzgerald | Initiated | Buy | $48 |
| Aug 6 | Morgan Stanley | Maintained | Buy | $38 |
| Aug 6 | Guggenheim | Maintained | Buy | $38 |
Technical Analysis
The stock is 9% below its 20 day and 1% below its 50 day average. It is 7% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 46). The nearest support is the Pivot at $27.25, and the nearest resistance the swing high (Sep 29) at $27.64.
| RSI (14) | 45.58 | Middle of its range | Neutral |
| MACD | -0.29 | Below its signal line | Bearish |
| Stochastic | 25.1 | Middle of its range | Neutral |
| ADX (14) | 21.4 | Weak trend | |
| Williams %R | -77.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -72.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −14.6% | Change over 10 sessions | Bearish |
| ATR (14) | $1.64 | Typical daily range, 6.0% of price |
| RSI (14) | 52.25 | Middle of its range | Neutral |
| MACD | 1.01 | Above its signal line | Bullish |
| Stochastic | 34.4 | Middle of its range | Neutral |
| ADX (14) | 20.2 | Weak trend | |
| Williams %R | -63.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 25.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +14.4% | Change over 10 sessions | Bullish |
| ATR (14) | $3.14 | Typical daily range, 11.5% of price |
What happened before
See how ARQT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ARQT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in ARQT in the last 90 days.
ARQT Institutional Ownership
Full report →- ▲183 buying vs 112 selling
- ▲Held by funds +13.9 pts
- ▲Funds holding +20
- ▲Superinvestors: 3 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 293 | 273 | +7.3% |
| In funds' top 10 | 6 | 5 | +20.0% |
| Held by funds | 117.8% | 104.0% | +13.9 pts |
| New / increased | 61 / 122 | 40 / 95 | +35.6% |
| Reduced / sold out | 70 / 42 | 101 / 38 | −19.4% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARQT is in one of them and how their past ARQT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ARQT in an article yet. Here's the latest on the wider market.
ARQT Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | May 29, 2026 | Jun 8, 2026 | 10 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Mar 3, 2026 | Apr 7, 2026 | 35 d |
| Gilbert CisnerosD · CA | Sell (partial) | $1K – $15K | Dec 11, 2025 | Jan 12, 2026 | 32 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Sep 15, 2023 | Oct 15, 2023 | 30 d |
| Josh GottheimerD · NJ | Buy | $1K – $15K | Apr 17, 2023 | May 19, 2023 | 32 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics is a biopharmaceutical company based in Westlake Village, California. It develops and sells treatments for skin conditions, mainly its ZORYVE line of topical creams and foam. These products treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in children and adults. Its customers include dermatologists, primary care practitioners, and pediatricians who prescribe them.
- Headquarters
- Westlake Village, CA





